INSPIRATION HEALTHCARE GROUP PLC

Report Publication Announcement • Oct 12, 2023

National Storage Mechanism | Additional information

RNS Number : 8487P

Inspiration Healthcare Group PLC

12 October 2023

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

ShareSoc investor presentation

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company pioneering best-in class, specialist neonatal intensive care medical devices, announces the Company will present at a ShareSoc investor event, in collaboration with Walbrook PR, on Thursday 19, October 2023. The presentation is open to all existing and potential shareholders who are members of ShareSoc.

The presentation will give an update on the Company and the strategic plans going forward over the next 12 months.

All attendees, both in-person and virtual, will have the opportunity to ask questions and those attending the seminar will be able to network with company directors and fellow investors over drinks and a buffet.

To register for the presentation and for further details, please use this link:

ShareSoc & Walbrook PR Healthcare Companies Hybrid Event, London - 19 October 2023, 5pm - ShareSoc

No new material information will be disclosed.

For further information, please contact:

Inspiration Healthcare Group plc		Tel: +44  (0)330 175 0000
Neil Campbell, Chief Executive Officer
Alan Olby, Chief Financial Officer
Walbrook PR Ltd (Media and Investor Relations)	Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com
Anna Dunphy		Mob: +44 (0) 7876 741 001
Stephanie Cuthbert		Mob: +44 (0) 7796 794 663
Louis Ashe-Jepson		Mob: +44 (0) 7747 515 393

About Inspiration Healthcare

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in neonatal intensive care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies.

The Company has key own brand products that can be used within the first days of life to help premature and sick babies; helping resuscitation and stabilisation in the first moments of life through to preventing brain damage and both invasive and non-invasive respiratory support in terms of capital equipment and disposable medical devices. Additionally, the Company has its own range of products for maintaining normothermia pre, during and post-surgery.

Since September 2019, the Company has acquired Vio Holdings a designer, manufacturer and supplier of single use respiratory products and sterile medical consumables and S.L.E., a leading designer, manufacturer and global provider of neonatal ventilation products.  The Group generates approximately 58% of its revenues from export markets and more than half of its revenues come from its own-branded products.

With product availability actively promoted to over 80 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe.

In the UK and Ireland, the Group has direct sales teams selling Group Branded and complementary products from third parties, with an additional range of home healthcare products.  This is supported by Technical Support for planned preventative maintenance and emergency assistance.

The Group operates from various sites in the UK for R&D, Marketing and operations with manufacturing based in Croydon (south London) and Hailsham (East Sussex).  The Group's Head Office is located in Crawley, a short distance from London's Gatwick Airport.

Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAGPGBAUUPWGMG